Scientific reports
January 6, 2023
Nicolas G Glynos, Lily Carter, Soo Jung Lee et al.
17 citations
Indolethylamine N-methyltransferase (INMT) is an enzyme known for producing the psychedelic compound DMT in mammalian brains. Researchers created INMT-knockout rats to determine whether INMT is necessary for DMT production. Brain and lung tissues from both normal and INMT-knockout rats showed equal levels of tryptamine-dependent activity, but the resulting products were neither NMT nor DMT. Rat INMT alone was also insufficient for producing NMT or DMT. These findings indicate an alternative enzymatic pathway for DMT biosynthesis exists in rats, motivating further investigation into how mammals produce DMT naturally.
Frontiers in psychiatry
January 1, 2024
Nicolas G Glynos, Jacob S Aday, Daniel Kruger et al.
15 citations
A large global survey of 5,268 adults who had used psychedelics found that nearly three-quarters (70.9%) reported ceasing or decreasing use of at least one non-psychedelic substance afterward. Among those who had previously used specific substances, 60.6% decreased alcohol use, 55.7% decreased antidepressant use, and 54.2% decreased cocaine or crack use. Over a quarter said the decrease lasted 26 weeks or longer. However, 19.8% reported increased or initiated use of other substances, most commonly illicit opioids (14.7%) and cannabis (13.3%). Factors linked to decreased use included motivation to reduce substance use or self-treat a medical condition; increased use was associated with higher income and residing in Canada or the US.
bioRxiv : the preprint server for biology
February 15, 2025
Nicolas G Glynos, Emma R Huels, Amanda Nelson et al.
11 citations
preprint
Intravenous DMT in rats caused dose-dependent increases in serotonin and dopamine in the medial prefrontal and somatosensory cortices, along with changes in brain wave patterns: reduced theta and low gamma power, increased delta, medium gamma, and high gamma power, and altered functional connectivity. All doses produced head twitch responses, most after the low dose. For the first time, endogenous DMT was measured in these cortical sites at levels comparable to serotonin and dopamine, suggesting a physiological role for the compound. The findings point to shared mechanisms with other psychedelics and support DMT's potential for treating psychiatric disorders.
Journal of psychoactive drugs
January 1, 2023
Daniel J Kruger, Nicolas G Glynos, Christopher W Fields et al.
10 citations
People who use psychedelics and have higher education, lower age, greater frequency of use, male gender, White/Caucasian identity, higher income, and experience with more types of psychedelics tend to know more about legal status, active compounds, and therapeutic efficacy. A survey of 1,435 participants recruited at a psychedelic advocacy event and online showed overall high knowledge, but gaps remain, highlighting the need for targeted education and harm reduction outreach, especially in under-represented communities.
Journal of psychoactive drugs
April 22, 2025
Nicolas G Glynos, Mallet R Reid, Jacob S Aday et al.
4 citations
People of Color have been underrepresented in psychedelic-assisted therapy (PAT) research, and some have suggested that systemic harms like the War on Drugs and discrimination in healthcare might reduce their willingness to participate. A large-scale survey of people using psychedelics in North America compared 3,547 White people, 448 People of Color, and 377 Multiracial people. A lower proportion of People of Color used psychedelics with a trained provider, but equal proportions had disclosed psychedelic use to primary care providers, were equally motivated to use psychedelics with a trained provider, used psychedelics for similar issues, and reported similar effectiveness. The findings suggest that lack of trust may not fully explain underrepresentation, and other barriers should be investigated.
Journal of psychopharmacology (Oxford, England)
May 1, 2025
Niloufar Pouyan, Jacob S Aday, Steven E Harte et al.
1 citation
People with treatment-resistant conditions often see their illness as part of their identity. The pictorial representation of illness and self measure (PRISM) gauges this self-condition enmeshment. In a survey of 297 individuals who used psychedelics therapeutically on their own, most reported symptom improvement: 95.4% with depression, 98.36% with posttraumatic stress disorder, and 94.87% with anxiety. PRISM scores dropped significantly after the most salient psychedelic experience, indicating reduced identification with the condition. The decrease in PRISM scores correlated with symptom improvement across all conditions. PRISM appears useful for tracking how psychedelics affect self-perception across diagnoses, though limitations include convenience sampling, potential positive bias, and retrospective reporting.
Journal of psychiatric research
June 2, 2026
Daniel J Kruger, Audrey Czerew, Leigh Farquhar et al.
The research priorities of people who have used psychedelics differ from those of institutional researchers. An online survey of 1192 U.S. adults who reported past psychedelic use identified seven major domains for future research: therapeutic efficacy, best practices for non-clinical use, safety and adverse experiences, broader understanding including indigenous traditions, non-medical outcomes like creativity and spiritual awakening, best practices for therapy, and best practices for research. Institutional researchers emphasized molecular, neurological, and clinical topics, while users prioritized non-clinical use and societal and cultural issues.